NRX Pharmaceuticals (NRXP) Accumulated Expenses (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 8 years of Accumulated Expenses data on file, last reported at $394000.0 in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 96.0% year-over-year to $394000.0 in Q1 2026; TTM through Mar 2026 was $394000.0, a 96.0% decrease from a year earlier, with the FY2025 full-year figure at $11.3 million, up 11.71% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $394000.0, down from $11.3 million in the prior quarter.
• Over the last five years, Accumulated Expenses for NRXP reached as high as $11.3 million in Q4 2025 and fell as low as $20000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $4.7 million across 5 years, with a median of $5.1 million in 2023.
• Across the five-year window, Accumulated Expenses jumped 25170.0% in 2023 and tumbled 96.0% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $923000.0 in 2022, then declined by 9.53% to $835000.0 in 2023, then surged by 1115.45% to $10.1 million in 2024, then gained by 11.71% to $11.3 million in 2025, then slumped by 96.52% to $394000.0 in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $394000.0 in Q1 2026, $11.3 million in Q4 2025, and $420000.0 in Q3 2025.